Carbendazim
Alternative Names: ATI-0312; Benzimate; FB 642Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Procter & Gamble
- Developer Arisyn Therapeutics
- Class Antifungals; Antineoplastics; Benzimidazoles; Carbamates; Small molecules
- Mechanism of Action Tubulin inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections in USA (PO)
- 23 Sep 2008 Arisyn Therapeutics acquires small-molecule inhibitors against infectious diseases and/or cancer from UAF Technologies and Research LLC, including carbendazim (ATI 0312)